Phibro Animal Health Got Some Bad News

By Carrie Williams

Macquarie analyst Matthew Brooks downgraded Phibro Animal Health (NASDAQ: PAHC) to Sell today. The company’s shares closed yesterday at $29.55.

According to, Brooks is a 2-star analyst with an average return of -1.4% and a 45.5% success rate. Brooks covers the Services sector, focusing on stocks such as Information Services Group, Speedway Motorsports, and ClubCorp Holdings.

Phibro Animal Health has an analyst consensus of Hold, with a price target consensus of $29.

Phibro Animal Health’s market cap is currently $1.16B and has a P/E ratio of 14.34. The company has a book value ratio of 12.8702.

Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PAHC in relation to earlier this year.

Phibro Animal Health Corp. is a developer, manufacturer and marketer of a broad range of animal health and mineral nutrition products for use in the production of poultry, swine, cattle, dairy and aquaculture. It operates through three business segment: Animal Health, Mineral Nutrition and Performance Products. The Animal Health segment develops, manufactures and markets antibacterials, nutritional specialty products, anticoccidials, vaccines and related products. The Mineral Nutrition segment manufactures and markets formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds. The Performance Products segment manufactures and markets a number of specialty ingredients for use in the personal care, automotive, industrial chemical and chemical catalyst industries, predominantly in the U.S. The company was founded in May 11, 1946 and is headquartered in Teaneck, NJ.